1 / 63

Collaborative Public Health Field Course January 2010

Collaborative Public Health Field Course January 2010. Lecture # 6 HTLV prevention and comprehensive care of people living with HTLV: challenges for the Brazilian healthcare system Aluisio Segurado Department of Infectious Diseases School of Medicine, University of São Paulo.

talisa
Download Presentation

Collaborative Public Health Field Course January 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Collaborative Public Health Field Course January 2010 Lecture # 6 HTLV prevention and comprehensive care of people living with HTLV: challenges for the Brazilian healthcare system AluisioSegurado Department of Infectious Diseases School of Medicine, University of São Paulo

  2. HTLV isolation and identification • HTLV-1 – cell line from ex vivo PBMC and lymphonode cells from patient with T-cell cutaneous lymphoma(Poeisz, 1980) • HTLV-2 – spleen cells from patient with hairy cell leukemia (Kalyanaraman, 1982)

  3. Retroviruses

  4. HTLV INFECTION Clinical and epidemiologic relevance • HTLV-1 – 15 - 20 million carriers worldwide lifetime risk of progression to disease  1- 5% • HTLV-2 – high prevalence in certain population groups low risk of progression to disease Mahieux, 1997; Salemi, 1999; Proietti, 2005

  5. GEOGRAPHICAL DISTRIBUTION HTLV - 1

  6. PREVALENCE OF HTLV-1 INFECTION

  7. GEOGRAPHICAL DISTRIBUTION HTLV - 1 37% (Mueller, 1996)

  8. GEOGRAPHICAL DISTRIBUTION HTLV - 1 <5% (Manns, 1999)

  9. GEOGRAPHICAL DISTRIBUTION HTLV - 1 <5% (Manns, 1999)

  10. GEOGRAPHICAL DISTRIBUTION HTLV - 1 <5% (Gessain, 1996, Sarkodie, 2001)

  11. GEOGRAPHICAL DISTRIBUTION HTLV - 1 <6% (Murphy, 1991)

  12. GEOGRAPHICAL DISTRIBUTION HTLV - 1 <2% (Leon, 2003)

  13. HTLV-1 INFECTION IN BRAZIL Serological screening in blood donors is mandatory since 1993 ESTIMATE: 2,500,000 HTLV-1 carriers Source: Proietti, 2005

  14. HTLV INFECTION SOROPREVALENCE AMONG BRAZILIAN BLOOD DONORS Proietti, 2002

  15. HTLV INFECTIONSOROPREVALENCE STUDIES IN BRAZIL HIV ASYMPTOMATIC CARRIERS 1% Caterino-Araújo, 94 AIDS PATIENTS, SP 10% Casseb, 94 HIV/AIDS PATIENTS, Santos 13.4% Etzel, 2001 MSM, RJ 4% Cortes, 93 COMERCIAL SEX WORKERS, RJ/MG 9% Cortes, 93 Santos 2.3% Bellei, 96 IDU, BA 35.2% Dourado, 98 BLOOD DONORS, SP 0.15% Ferreira Jr, 95 RJ 0.42-0.78% Carvalho, 97 PE 0.6% Loureiro, 96 BA 1.35% Galvão-Castro, 97 PREGNANT WOMEN, BA 0.84% Bittencourt, 2001 POPULATION-BASED SURVEY – Salvador, BA 1.76% Dourado, 2003

  16. HTLV INFECTIONSOROPREVALENCE STUDIES IN BRAZIL Nationwide sentinel study pregnant women

  17. GEOGRAPHICAL DISTRIBUTION HTLV - 1 0.84 – 1.76% (Bittencourt, 2001; Dourado, 2003)

  18. GEOGRAPHICAL DISTRIBUTION HTLV - 2

  19. HTLV- 1 andHTLV- 2 • GENETIC SIMILARITY = 65 % • GENOTYPIC VARIANTS

  20. HTLV TRANSMISSION ROUTES • SEXUAL • BLOOD-BORNE – cellular components, IDU • MOTHER-TO-CHILD– breast feeding Kinoshita, 1984; Hino, 1997; Manns, 1992 and 1999; Etzel, 2001

  21. SEXUAL TRANSMISSION • Miyazaki cohort • more efficient from infected males to female susceptible partner • associated with long-term sexual partnerships • associated with age of susceptible female partner • postmenopausal women – more vulnerable • depends on local factors – female genital tract Mueller, 1996

  22. SEXUAL TRANSMISSION • HOST cohort, blood donors, USA • 85 donors: follow-up every 2 years for 10 y (30 HTLV-1+ and 55 HTLV-2+) - steady sexual partnerships • 4 soroconversions  incidence = 0.6 / 100 PYFU (95%CI 0.2 – 1.6) • 2 HTLV-1 / 219 PYFU  0.9 / 100 PYFU (0.1 – 3.3) • 2 HTLV-2 / 411 PYFU  0.4 / 100 PYFU (0.05 – 1.6) • 2 cases M  F and 2 cases F  M Roucoux, 2005

  23. MTCT • Jamaican cohort • associated with anti-HTLV antibody titres (RR = 2.2/quartile) • associated with HTLV proviral load in blood (RR = 1.9/quartile) and breast milk (RR = 2.34/quartile) • dose-response relationship between risk of MTCT by breastfeeding and HLA class I concordance between mother and child • longer survival of maternal cells ? • independent from maternal proviral load, antibody titres and income Hisada, 2002; Li, 2004; Biggar, 2006

  24. HTLV TRANSMISSION Unanswered questions • few quantitative data on incident infections • frequencies vary among populations • frequencies vary in time • impact evaluation of preventive measures • Challenge for prevention low adherence to long-term condom use in steady sexual partnerships

  25. HTLV-1 infection - Natural history - Acute infection Integration to genome Viral persistence – life-long infection Asymptomatic carrier HTLV-1-associated diseases 100% 100% >95% <5%

  26. HTLV-1- RELATED DISEASES • ADULT T-CELL LEUKEMIA/LYMPHOMA (ATL/L) • HTLV-1-ASSOCIATED MYELOPATHY / TROPICAL SPASTIC PARAPARESIS / (HAM/TSP) • INFLAMMATORY SYNDROMES: UVEITIS, ARTHRITIS, POLYMIOSITIS, SJÖGREN SYNDROME, INFECTIVE DERMATITIS, PNEUMONITIS

  27. HTLV-1-RELATED DISEASE IN BRAZIL • ATL/L – Oliveira, 1990 • HAM/TSP – Castro, 1989 Spina-França, 1990

  28. PROGNOSTIC MARKERS – HTLV DISEASE DEVELOPMENT – • Proviral load (Taylor, 99) • Monoclonal expansion of infected CD4+ T cells (Takemoto, 94) • Genetic susceptibility (Jeffery, 99)

  29. PROGNOSTIC FACTORS • Methodological limitations • low prevalence of HTLV infection in many areas • HTLV-related diseases are rare • natural history – long time interval to disease development • few cohorts of asymptomatic carriers

  30. PROGNOSTIC FACTORS • ATL • HLA genetic polymorphisms • Ethnic and family clusters not related to HAM/TSP • ATL-associated (vs. HAM/TSP and asymptomatic carriers) • HLA-A*26, -B*4002, -B*4006 and -B*4801 • less intense CD8+ anti-Tax response Yashiki, 2001

  31. PROGNOSTIC FACTORS • HAM/TSP • HLA genetic polymorphism - Kagoshima cohort • protective haplotypes – HLA-A*02, HLA-CW*08 • associated with lower proviral load • risk-associated haplotypes – HLA-DRB-1, HLA-B54 Saito, 2005

  32. PROGNOSTIC FACTORS • Clinical markers (infective dermatitis) • Mode of exposure to HTLV infection

  33. PROGNOSTIC FACTORS • Risk of ATL = higher for men infected at early ages • varies according to age when infected • Japan > Caribbean • Risk of HAM/TSP = higher for women infected after weaning • Caribbean > Japan

  34. HTLV-2-RELATED DISEASES • CHRONIC MYELOPATHY - HAM/TSP-like • SENSITIVE POLYNEUROPATHIES • INFLAMMATORY MYOPATHIES

  35. SURVIVAL • HOST STUDY • prospective cohort study – blood donors, 5 centers, USA • 152 HTLV-1+, 387 HTLV-2+, and 799 uninfected donors • follow-up visits every 2 years since 1992 • Survival • median follow-up of 8.6 years 45 deaths • HTLV-1 infection - unadjusted HR 1.9 (95%CI 0.8-4.4); adjusted HR 1.9 (95%CI 0.8-4.6) • HTLV-2 infection - unadjusted HR 2.8 (95%CI 1.5-5.5); adjusted HR 2.3 (95%CI 1.1-4.9) Orland, 2004

  36. SURVIVAL • HOST STUDY Orland, 2004

  37. DISEASE OUTCOMES • HOST STUDY • HTLV-2+ donors  acute bronchitis (incidence ratio [IR] = 1.68), bladder or kidney infection (IR = 1.55), arthritis (IR = 2.66), and asthma (IR = 3.28); pneumonia (IR = 1.82, 95% confidence interval [CI] 0.98 to 3.38) • HTLV-1+ participants bladder or kidney infection (IR = 1.82), and arthritis (IR = 2.84) Murphy, 2004

  38. CARE OF PEOPLE LIVING WITH HTLV

  39. CUIDADO/CARE • Diligência, desvelo, zelo – Close attention Sempretevecuidado com seuslivros. He painted the window frames with care. • Encargo, responsabilidade – Watchful oversight, charge/supervision Deixei a encomenda dos livros sob seuscuidados. They left the child in the care of a neighbour. Sources: Aurélio Buarque de Holanda, Portuguese Dictionary www. Thefreedictionary.com

  40. HTLV CARE • Involvement of members of the Brazilian scientific and healthcare communities

  41. HTLV CARE • Involvement of members of the Brazilian scientific and healthcare communities • Governmental initiative

  42. HTLV CARE • Involvement of members of the Brazilian scientific and healthcare communities • Governmental initiative National guidelines, 2004

  43. HTLV CARE • Involvement of members of the Brazilian scientific and healthcare communities • Governmental initiative National guidelines, 2004 available @ <http//www.aids.gov.br

  44. HTLV CARE • How successful have we been so far in providing care to people living with HTLV with the ultimate goal of improving their quality of life?

  45. Challenges • Information about the epidemiology and natural history of HTLV infection is still limited • Access to serodiagnostic tools is not available in many areas (confirmatory tests) • Performance of diagnostic tests • significant proportion of indeterminate results when applied in screening • low sensitivity to detect HTLV-2 infection

  46. Diagnostic algorithm for HTLV-1 and HTLV-2 infections Brazil, Ministry of Health, 2004

  47. Challenges • Alternative algorithms for diagnostic confirmation  molecular biology methods • not available for routine use • not widely available for research • not standardized and lack quality control • operational barriers – nested PCR protocols, detection using radioisotopic probes

  48. INFECTIOUS DISEASES OUTPATIENT CLINICHospital das Clínicas - FMUSP HTLV Clinic • Opened in August 1991 • Clients include • HTLV asymptomatic carriers • HTLV-related diseases

  49. Challenges • Unavailability of a national program to address HTLV prevention and care • Department of HIV/STD/Hepatitis – Ministry of Health • Primary care level

  50. Challenges • Unavailability of a healthcare referral system • prevents patients from accessing standard of care technologies • distresses both patients and healthcare professionals

More Related